Attached files
file | filename |
---|---|
8-K - AzurRx BioPharma, Inc. | form8k-04142020_020435.htm |
Exhibit 99.1
AzurRx Appoints Gregory Oakes to its Board of
Directors
Seasoned veteran with decades of strategic and global leadership
experience
NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.
(NASDAQ:AZRX)
(“AzurRx” or the “Company”) a company
specializing in the development of non-systemic, recombinant
therapies for gastrointestinal diseases today announced the
appointment of Gregory Oakes to the Board of Directors effective
April 13, 2020.
“Greg is a strong and welcomed addition to our board,”
said James Sapirstein, CEO of AzurRx BioPharma. “His broad
experience in pharmaceutical commercialization and acquisitions
will help AzurRx as we advance MS1819 through two Phase 2 clinical
studies in 2020 and intensify our partnering
discussions.”
"I am excited to join the AzurRx Board with its compelling
potential synthetic alternative to PERT therapy,” said Mr.
Oakes. “I look forward to helping the Company realize the
full commercial potential of the MS1819 program."
Mr. Oakes brings to the AzurRx Board over 25 years of
pharmaceutical industry and leadership experience. He
currently serves as Corporate Vice President – Global
integration Lead for Otezla at Amgen where he is overseeing the
integration and continued success of the $2B brand and positioning
it for sustained growth. Prior to Amgen, Mr. Oakes was
Corporate Vice President and US General Manager at Celgene.
Mr. Oakes also served as the Global Commercial Integration Lead at
Celgene where he helped steer the $74B acquisition by Bristol-Myers
Squibb and the $13.4B divestiture of Otezla. Prior to
Celgene, Mr. Oakes held several positions at Novartis, most
recently as Head of Sandoz Biopharmaceuticals, North America.
He began his career at Schering-Plough (Merck) where he held
executive roles both in the US and Europe. He holds a
bachelor’s degree in Marketing and Business Administration
from Edinboro University and a M.B.A. from Clemson
University. He currently sits on the Board of BioNJ and
served on various Executive Committees at Celgene, Novartis, and
Schering-Plough (Merck).
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is a biopharmaceutical company
engaged in the research and development of non-systemic biologics
for the treatment of patients with gastrointestinal disorders. The
Company’s lead drug candidate, MS1819, is a recombinant
lipase enzyme for the treatment of exocrine pancreatic
insufficiency (EPI) associated with cystic fibrosis (CF) and
chronic pancreatitis (CP). The Company is headquartered in New
York, NY, with scientific operations based in Langlade,
France. Additional information on the Company can be found
at www.azurrx.com.
Forward-Looking Statements
This press release may contain certain statements relating to
future results which are forward-looking statements. These
statements are not historical facts, but instead represent only the
Company’s belief regarding future events, many of which, by
their nature, are inherently uncertain and outside of the
Company’s control. It is possible that the Company’s
actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in these forward-looking statements. Additional
information concerning the Company and its business, including a
discussion of factors that could materially affect the
Company’s financial results, including those related to the
clinical development of MS1819 and the results of its clinical
trials, are contained in the Company’s Annual Report on Form
10-K for the year ended December 31, 2019 under the
heading “Risk Factors,” as well as the
Company’s subsequent filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become
aware.
For more information:
AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn, NY 11226
Phone: (646)-699-7855
info@azurrx.com
Investor Relations contact:
LifeSci Advisors, LLC.
Hans Vitzthum, Managing Director
1 International Place, Suite 1480
Boston, MA 02110
Phone: 617-430-7578
hans@lifesciadvisors.com